Skip to main content

Advertisement

SpringerLink
Log in

Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects

  • CELL TECHNOLOGIES IN BIOLOGY AND MEDICINE
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Epidermolysis bullosa is a severe hereditary disease caused by mutations in genes encoding cutaneous basement membrane proteins. These mutations lead to dermal-epidermal junction failure and, as a result, to disturbances in the morphological integrity of the skin. Clinically, it manifests in the formation of blisters on the skin or mucosa that in some cases can turn into non-healing chronic wounds, which not only impairs patient’s quality of life, but also is a live-threatening condition. Now, the main approaches in the treatment of epidermolysis bullosa are symptomatic therapy and palliative care, though they are little effective and are aimed at reducing the pain, but not to complete recovery. In light of this, the development of new treatment approaches aimed at correction of genetic defects is in progress. Various methods based on genetic engineering technologies, transplantation of autologous skin cells, progenitor skin cells, as well as hematopoietic and mesenchymal stem cells are studied. This review analyzes the pathogenetic methods developed for epidermolysis bullosa treatment based on the latest achievements of molecular genetics and cellular technologies, and discusses the prospects for the use of these technologies for the therapy of epidermolysis bullosa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atkinson SD, McGilligan VE, Liao H, Szeverenyi I, Smith FJ, Moore CB, McLean WH. Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J. Invest. Dermatol. 2011;131(10):2079-2086. doi: https://doi.org/10.1038/jid.2011.169

    Article  CAS  PubMed  Google Scholar 

  2. Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, Bondanza S, Recchia A, Muss W, Diem A, Mayr E, Schlager P, Gratz IK, Pellegrini G, De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J. Invest. Dermatol. 2017;137(3):778-781. doi: https://doi.org/10.1016/j.jid.2016.10.038

    Article  CAS  PubMed  Google Scholar 

  3. Bauer JW, Lanschuetzer C. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin. Exp. Dermatol. 2003;28(1):53-60. doi: https://doi.org/10.1046/j.1365-2230.2003.01192.x

    Article  CAS  PubMed  Google Scholar 

  4. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell. 2007;128(3):445-458. doi: https://doi.org/10.1016/j.cell.2007.01.014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 1985;13(17):6265-6272. doi: https://doi.org/10.1093/nar/13.17.6265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chamorro C, Mencía A, Almarza D, Duarte B, Büning H, Sallach J, Hausser I, Del Río M, Larcher F, Murillas R. Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes. Mol. Ther. Nucleic Acids. 2016;5(4):e307. doi: https://doi.org/10.1038/mtna.2016.19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 2003;8(3):495-500. doi: https://doi.org/10.1016/s1525-0016(03)00168-0

    Article  CAS  PubMed  Google Scholar 

  8. Chiavérini C, Charlesworth A, Meneguzzi G, Lacour J.P, Ortonne J.P. Epidermolysis bullosa simplex with muscular dystrophy. Dermatol. Clin. 2010;28(2):245-255, viii. doi: https://doi.org/10.1016/j.det.2010.01.001

    Article  CAS  PubMed  Google Scholar 

  9. Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, Gonzalez S, Yubero MJ. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010;12(3):429-431. doi: https://doi.org/10.3109/14653241003587637

    Article  CAS  PubMed  Google Scholar 

  10. Coulombe PA, Kerns ML, Fuchs E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J. Clin. Invest. 2009;119(7):1784-1793. doi: https://doi.org/10.1172/JCI38177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Coulombe PA, Lee CH. Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath. J. Invest. Dermatol. 2012;132(3, Pt 2):763-775. doi: https://doi.org/10.1038/jid.2011.450

  12. Cuadrado-Corrales N, Sánchez-Jimeno C, García M, Escámez MJ, Illera N, Hernández-Martín A, Trujillo-Tiebas MJ, Ayuso C, Del Rio M. A prevalent mutation with founder effect in Spanish recessive dystrophic epidermolysis bullosa families. BMC Med. Genet. 2010;11:139. doi: https://doi.org/10.1186/1471-2350-11-139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dang N, Klingberg S, Rubin AI, Edwards M, Borelli S, Relic J, Marr P, Tran K, Turner A, Smith N, Murrell DF. Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literature. Acta Derm. Venereol. 2008;88(5):438-448. doi: https://doi.org/10.2340/00015555-0484

    Article  CAS  PubMed  Google Scholar 

  14. Davies J, Gilbert W, Gorini L. Streptomycin, suppression, and the code. Proc. Natl Acad. Sci. USA. 1964;51(5):883-890. doi: https://doi.org/10.1073/pnas.51.5.883

    Article  CAS  PubMed  Google Scholar 

  15. De Luca M, Pellegrini G, Green H. Regeneration of squamous epithelia from stem cells of cultured grafts. Regen. Med. 2006;1(1):45-57. doi: https://doi.org/10.2217/17460751.1.1.45

    Article  PubMed  Google Scholar 

  16. De Luca M, Pellegrini G, Mavilio F. Gene therapy of inherited skin adhesion disorders: a critical overview. Br. J. Dermatol. 2009;161(1):19-24. doi: https://doi.org/10.1111/j.1365-2133.2009.09243.x

    Article  CAS  PubMed  Google Scholar 

  17. De Ravin SS, Su L, Theobald N, Choi U, Macpherson JL, Poidinger M, Symonds G, Pond SM, Ferris AL, Hughes SH, Malech HL, Wu X. Enhancers are major targets for murine leukemia virus vector integration. J. Virol. 2014;88(8):4504-4513. doi: https://doi.org/10.1128/JVI.00011-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. De Rosa L, Carulli S, Cocchiarella F, Quaglino D, Enzo E, Franchini E, Giannetti A, De Santis G, Recchia A, Pellegrini G, De Luca M. Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa. Stem Cell Reports. 2013;2(1):1-8. doi: https://doi.org/10.1016/j.stemcr.2013.11.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Di Nunzio F, Maruggi G, Ferrari S, Di Iorio E, Poletti V, Garcia M, Del Rio M, De Luca M, Larcher F, Pellegrini G, Mavilio F. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol. Ther. 2008;16(12):1977-1985. doi: https://doi.org/10.1038/mt.2008.204

    Article  CAS  PubMed  Google Scholar 

  20. Dul M, Stefanidou M, Porta P, Serve J, O’Mahony C, Malissen B, Henri S, Levin Y, Kochba E, Wong FS, Dayan C, Coulman SA, Birchall JC. Hydrodynamic gene delivery in human skin using a hollow microneedle device. J. Control. Release. 2017;265:120-131. doi: https://doi.org/10.1016/j.jconrel.2017.02.028

    Article  CAS  PubMed  Google Scholar 

  21. El-Darouti M, Fawzy M, Amin I, Abdel Hay R, Hegazy R, Gabr H, El Maadawi Z. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial. Dermatol. Ther. 2016;29(2):96-100. doi: https://doi.org/10.1111/dth.12305

    Article  PubMed  Google Scholar 

  22. Fine JD. Inherited epidermolysis bullosa. Orphanet J. Rare Dis. 2010;5:12. doi: https://doi.org/10.1186/1750-1172-5-12

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J. Am. Acad. Dermatol. 2014;70(6):1103-1126. doi: https://doi.org/10.1016/j.jaad.2014.01.903

    Article  PubMed  Google Scholar 

  24. Fine JD, Eady RA, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A, Heagerty A, Hintner H, Jonkman MF, McGrath J, McGuire J, Moshell A, Shimizu H, Tadini G, Uitto J. Revised classification system for inherited epidermolysis bullosa: Report of the second international consensus meeting on diagnosis and classification of epidermolysis bullosa. J. Am. Acad. Dermatol. 2000;42(6):1051-1066.

    Article  CAS  Google Scholar 

  25. Finkel RS, Flanigan KM, Wong B, Bönnemann C, Sampson J, Sweeney HL, Reha A, Northcutt VJ, Elfring G, Barth J, Peltz SW. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One. 2013;8(12):e81302. doi: https://doi.org/10.1371/journal.pone.0081302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gambardella L, Barrandon Y. The multifaceted adult epidermal stem cell. Curr. Opin. Cell Biol. 2003;15(6):771-777. doi: https://doi.org/10.1016/j.ceb.2003.10.011

    Article  CAS  PubMed  Google Scholar 

  27. Georgiadis C, Syed F, Petrova A, Abdul-Wahab A, Lwin SM, Farzaneh F, Chan L, Ghani S, Fleck RA, Glover L, McMillan JR, Chen M, Thrasher AJ, McGrath JA, Di WL, Qasim W. Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore anchoring fibrils in RDEB. J. Invest. Dermatol. 2016;136(1):284-292. doi: https://doi.org/10.1038/JID.2015.364

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gorell E, Nguyen N, Lane A, Siprashvili Z. Gene therapy for skin diseases. Cold Spring Harb. Perspect. Med. 2014;4(4):a015149. doi: https://doi.org/10.1101/cshperspect.a015149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gostyńska KB, Yenamandra VK, Lindemans C, Duipmans J, Gostyński A, Jonkman MF, Boelens JJ. Allogeneic haematopoietic cell transplantation for epidermolysis bullosa: the Dutch experience. Acta Derm. Venereol. 2019;99(3):347-348. doi: https://doi.org/10.2340/00015555-3097

    Article  CAS  PubMed  Google Scholar 

  30. Gostynski A, Deviaene F.C, Pasmooij AM, Pas HH, Jonkman MF. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br. J. Dermatol. 2009;161(2):444-447. doi: https://doi.org/10.1111/j.1365-2133.2009.09118.x

    Article  CAS  PubMed  Google Scholar 

  31. Gostyński A, Pasmooij AM, Jonkman MF. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J. Am. Acad. Dermatol. 2014;70(1):98-101. doi: https://doi.org/10.1016/j.jaad.2013.08.052

    Article  PubMed  Google Scholar 

  32. Guerra L, Odorisio T, Zambruno G, Castiglia D. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development. Matrix Biol. 2017;63:1-10. doi: https://doi.org/10.1016/j.matbio.2017.01.002

    Article  CAS  PubMed  Google Scholar 

  33. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCIDX1. Science. 2003;302:415-419. doi: https://doi.org/10.1126/science.1088547

    Article  CAS  PubMed  Google Scholar 

  34. Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H. Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa. J. Invest. Dermatol. 2016;136(11):2150-2157. doi: https://doi.org/10.1016/j.jid.2016.06.609

    Article  CAS  PubMed  Google Scholar 

  35. Haneke E, Anton-Lamprecht I. Ultrastructure of Blister Formation in Epidermolysis Bullosa Hereditaria: V. Ultrastructure of blister formation in epidermolysis bullosa hereditaria: V. Epidermolysis bullosa simplex localisata type Weber-Cockayne. J. Invest. Dermatol. 1982;78(3):219-223. doi: https://doi.org/10.1111/1523-1747.ep12506502

    Article  CAS  PubMed  Google Scholar 

  36. Has C, Bruckner-Tuderman L. The genetics of skin fragility. Annu. Rev. Genomics Hum. Genet. 2014;15:245-268. doi: https://doi.org/10.1146/annurev-genom-090413-025540

    Article  CAS  PubMed  Google Scholar 

  37. Has C, Herz C, Zimina E, Qu HY, He Y, Zhang ZG, Wen TT, Gache Y, Aumailley M, Bruckner-Tuderman L. Kindlin-1 is required for RhoGTPase-mediated lamellipodia formation in keratinocytes. Am. J. Pathol. 2009;175(4):1442-1452. doi: https://doi.org/10.2353/ajpath.2009.090203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hovnanian A. Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation? J. Invest. Dermatol. 2013;133(7):1719-1721. doi: https://doi.org/10.1038/jid.2013.137

    Article  CAS  PubMed  Google Scholar 

  39. Kaviarasan PK, Prasad PV, Shradda, Viswanathan P. Kindler syndrome. Indian J. Dermatol. Venereol. Leprol. 2005; 71(5):348-350. doi: https://doi.org/10.4103/0378-6323.16788

    Article  CAS  PubMed  Google Scholar 

  40. Kiritsi D, Huilaja L, Franzke CW, Kokkonen N, Pazzagli C, Schwieger-Briel A, Larmas M, Bruckner-Tuderman L, Has C, Tasanen K. Junctional epidermolysis bullosa with LAMB3 splice-site mutations. Acta Derm. Venereol. 2015;95(7):849-851. doi: https://doi.org/10.2340/00015555-2073

    Article  CAS  PubMed  Google Scholar 

  41. Kocher T, Peking P, Klausegger A, Murauer EM, Hofbauer JP, Wally V, Lettner T, Hainzl S, Ablinger M, Bauer JW, Reichelt J, Koller U. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases. Mol. Ther. 2017;25(11):2585-2598. doi: https://doi.org/10.1016/j.ymthe.2017.08.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis bullosa acquisita: the 2019 update. Front. Med (Lausanne). 2019;5:362. doi: https://doi.org/10.3389/fmed.2018.00362

    Article  Google Scholar 

  43. LaFave MC, Varshney GK, Gildea DE, Wolfsberg TG, Baxevanis AD, Burgess SM. MLV integration site selection is driven by strong enhancers and active promoters. Nucleic Acids Res. 2014;42(7):4257-4269. doi: https://doi.org/10.1093/nar/gkt1399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lai-Cheong JE, McGrath JA, Uitto J. Revertant mosaicism in skin: natural gene therapy. Trends Mol. Med. 2011;17(3):140-148. doi: https://doi.org/10.1016/j.molmed.2010.11.003

    Article  PubMed  Google Scholar 

  45. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL. First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Mol. Ther. 2010;18(2):442-446. doi: https://doi.org/10.1038/mt.2009.273

    Article  CAS  PubMed  Google Scholar 

  46. Lee HL, Dougherty JP. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol. Ther. 2012;136(2):227-266. doi: https://doi.org/10.1016/j.pharmthera.2012.07.007

    Article  CAS  PubMed  Google Scholar 

  47. Longo V, Rebulla P, Pupella S, Zolla L, Rinalducci S. Proteomic characterization of platelet gel releasate from adult peripheral and cord blood. Proteomics Clin. Appl. 2016;10(8):870-882. doi: https://doi.org/10.1002/prca.201500126

    Article  CAS  PubMed  Google Scholar 

  48. Mabuchi E, Umegaki N, Murota H, Nakamura T, Tamai K, Katayama I. Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation. Br. J. Dermatol. 2007;157(3):596-598. doi: https://doi.org/10.1111/j.1365-2133.2007.08046.x

    Article  CAS  PubMed  Google Scholar 

  49. March OP, Reichelt J, Koller U. Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders. Exp. Physiol. 2018;103(4):449-455. doi: https://doi.org/10.1113/EP086044

    Article  CAS  PubMed  Google Scholar 

  50. Mauritz P, Jonkman MF, Visser SS, Finkenauer C, Duipmans JC, Hagedoorn M. Impact of painful wound care in epidermolysis bullosa during childhood: an interview study with adult patients and parents. Acta Derm. Venereol. 2019;99(9):783-788. doi: https://doi.org/10.2340/00015555-3179

    Article  PubMed  Google Scholar 

  51. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, Capurro S, Conti A, Magnoni C, Giannetti A, De Luca M. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 2006;12(12):1397-1402. doi: https://doi.org/10.1038/nm1504

    Article  CAS  PubMed  Google Scholar 

  52. McBride JD, Rodriguez-Menocal L, Candanedo A, Guzman W, Garcia-Contreras M, Badiavas EV. Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts. Biochimie. 2018;155:50-58. doi: https://doi.org/10.1016/j.biochi.2018.04.007

    Article  CAS  PubMed  Google Scholar 

  53. McGrath JA. Recently identified forms of epidermolysis bullosa. Ann. Dermatol. 2015;27(6):658-666. doi: https://doi.org/10.5021/ad.2015.27.6.658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Morgan CP, Allen DSI, Millington-Ward S, O’Dwyer GE, Palfi A, Jane Farrar G. A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2013;133(12):2793-2796. doi: https://doi.org/10.1038/jid.2013.241

    Article  CAS  PubMed  Google Scholar 

  55. Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, Meneguzzi G, Hintner H, Bauer JW. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2011;131(1):74-83. doi: https://doi.org/10.1038/jid.2010.249

    Article  CAS  PubMed  Google Scholar 

  56. Murauer EM, Koller U, Pellegrini G, De Luca M, Bauer JW. Advances in gene/cell therapy in epidermolysis bullosa. Keio J. Med. 2015;64(2):21-25. doi: https://doi.org/10.2302/kjm.2014-0013-RE

    Article  CAS  PubMed  Google Scholar 

  57. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267. doi: https://doi.org/10.1126/science.272.5259.263

    Article  CAS  PubMed  Google Scholar 

  58. Nanba D. Human keratinocyte stem cells: from cell biology to cell therapy. J. Dermatol. Sci. 2019;96(2):66-72. doi: https://doi.org/10.1016/j.jdermsci.2019.10.002

    Article  CAS  PubMed  Google Scholar 

  59. Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv. Biomed. Res. 2012;1:27. doi: https://doi.org/10.4103/2277-9175.98152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Nyström A, Bruckner-Tuderman L. Gene therapy for epidermolysis bullosa: sticky business. Mol. Ther. 2016;24(12):2035-2036. doi: https://doi.org/10.1038/mt.2016.199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. O’Connor N, Mulliken JB, Banks-Schlegel S, Kehinde O, Green H. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet. 1981;1:75-78.

    Article  Google Scholar 

  62. Peking P, Koller U, Hainzl S, Kitzmueller S, Kocher T, Mayr E, Nyström A, Lener T, Reichelt J, Bauer JW, Murauer EM. A gene gun-mediated nonviral RNA trans-splicing strategy for Col7a1 repair. Mol. Ther. Nucleic Acids. 2016;5:e287. doi: https://doi.org/10.1038/mtna.2016.3

    Article  CAS  PubMed  Google Scholar 

  63. Peking P, Koller U, Murauer EM. Functional therapies for cutaneous wound repair in epidermolysis bullosa. Adv. Drug Deliv. Rev. 2018;129:330-343. doi: https://doi.org/10.1016/j.addr.2017.12.003

    Article  CAS  PubMed  Google Scholar 

  64. Pendaries V, Gasc G, Titeux M, Tonasso L, Mejía JE, Hovnanian A. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2012;132(6):1741-1743. doi: https://doi.org/10.1038/jid.2012.11

    Article  CAS  PubMed  Google Scholar 

  65. Perdoni C, Osborn MJ, Tolar J. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa. Transl. Res. 2016;168:50-58. doi: https://doi.org/10.1016/j.trsl.2015.05.008

    Article  CAS  PubMed  Google Scholar 

  66. Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, Ofuya M, Peacock JL, Martinez AE, McGrath JA. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2015;135(9):2319-2321. doi: https://doi.org/10.1038/jid.2015.158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, Mc-Grath JA. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br. J. Dermatol. 2013;169(5):1025-1033. doi: https://doi.org/10.1111/bjd.12599

    Article  CAS  PubMed  Google Scholar 

  68. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS. Nanoparticles and microparticles for skin drug delivery. Adv. Drug Deliv. Rev. 2011;63(6):470-491. doi: https://doi.org/10.1016/j.addr.2011.01.012

    Article  CAS  PubMed  Google Scholar 

  69. Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rübsam M, Huber A, Chiorini J, Almarza D, Eming SA, Ulus H, Nishimura S, Hacker UT, Hallek M, Niessen CM, Büning H. Tropismmodified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 2014;22(5):929-939. doi: https://doi.org/10.1038/mt.2014.14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Schepeler T, Page ME, Jensen KB. Heterogeneity and plasticity of epidermal stem cells. Development. 2014;141(13):2559-2567. doi: https://doi.org/10.1242/dev.104588

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Schröder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521-529. doi: https://doi.org/10.1016/s0092-8674(02)00864-4

    Article  PubMed  Google Scholar 

  72. Shinkuma S. Dystrophic epidermolysis bullosa: a review. Clin. Cosmet. Invest. Dermatol. 2015;8:275-284. doi https://doi.org/https://doi.org/10.2147/CCID.S54681

  73. Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc. Natl Acad. Sci. USA. 2016;113(20):5676-5681. doi: https://doi.org/10.1073/pnas.1512028113

    Article  CAS  PubMed  Google Scholar 

  74. Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich MP, Lane AT, Khavari PA. Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue. Hum. Gene Ther. 2010;21(10):1299-1310. doi: https://doi.org/10.1089/hum.2010.023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808-1817. doi: https://doi.org/10.1001/jama.2016.15588

    Article  PubMed  Google Scholar 

  76. Soro L, Bartus C, Purcell S. Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies. J. Clin. Aesthet Dermatol. 2015;8(5):41-46.

    PubMed  PubMed Central  Google Scholar 

  77. Tockner B, Kocher T, Hainzl S, Reichelt J, Bauer JW, Koller U, Murauer EM. Construction and validation of an RNA transsplicing molecule suitable to repair a large number of COL7A1 mutations. Gene Ther. 2016;23(11):775-784. doi: https://doi.org/10.1038/gt.2016.57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, Wagner JE, Blazar BR. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 2009;113(5):1167-1174. doi: https://doi.org/10.1182/blood-2008-06-161299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Turczynski S, Titeux M, Pironon N, Hovnanian A. Antisensemediated exon skipping to reframe transcripts. Methods Mol. Biol. 2012;867:221-238. doi: https://doi.org/10.1007/978-1-61779-767-5_15

    Article  CAS  PubMed  Google Scholar 

  80. Uitto J, Bruckner-Tuderman L, McGrath JA, Riedl R, Robinson C. EB2017 — Progress in epidermolysis bullosa research toward treatment and cure. J. Invest. Dermatol. 2018;138(5):1010-1016. doi: https://doi.org/10.1016/j.jid.2017.12.016

    Article  CAS  PubMed  Google Scholar 

  81. Umegaki-Arao N, Pasmooij AM, Itoh M, Cerise JE, Guo Z, Levy B, Gostyński A, Rothman LR, Jonkman MF, Christiano AM. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa. Sci. Transl. Med. 2014;6(264):264ra164. doi: https://doi.org/10.1126/scitranslmed.3009342

    Article  CAS  PubMed  Google Scholar 

  82. Ussar S, Moser M, Widmaier M, Rognoni E, Harrer C, Genzel-Boroviczeny O, Fässler R. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet. 2008;4(12):e1000289. doi: https://doi.org/10.1371/journal.pgen.1000289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. van den Akker PC, Jonkman MF, Rengaw T, Bruckner-Tuderman L, Has C, Bauer JW, Klausegger A, Zambruno G, Castiglia D, Mellerio JE, McGrath JA, van Essen AJ, Hofstra RM, Swertz MA. The international dystrophic epidermolysis bullosa patient registry: An online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum. Mutat. 2011;32(10):1100-1107. doi: https://doi.org/10.1002/humu.21551

    Article  CAS  PubMed  Google Scholar 

  84. Vanden Oever M, Twaroski K, Osborn MJ, Wagner JE, Tolar J. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatr. Res. 2018;83(1-2):318-324. doi: https://doi.org/10.1038/pr.2017.244.

    Article  CAS  Google Scholar 

  85. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 2010;363(7):629-639. doi: https://doi.org/10.1056/NEJMoa0910501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Wally V, Brunner M, Lettner T, Wagner M, Koller U, Trost A, Murauer EM, Hainzl S, Hintner H, Bauer JW. K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum. Mol. Genet. 2010;19(23):4715-4725. doi: https://doi.org/10.1093/hmg/ddq405

    Article  CAS  PubMed  Google Scholar 

  87. Wally V, Klausegger A, Koller U, Lochmüller H, Krause S, Wiche G, Mitchell LG, Hintner H, Bauer JW. 5’ trans-splicing repair of the PLEC1 gene. J. Invest. Dermatol. 2008;128(3): 568-574. doi: https://doi.org/10.1038/sj.jid.5701152

    Article  CAS  PubMed  Google Scholar 

  88. Weber F, Bauer JW, Sepp N, Högler W, Salmhofer W, Hintner H, Fritsch P. Squamous cell carcinoma in lunctional and dystrophic epidermolysis bullosa. Acta Derm. Venereol. 2001;81:189-192. doi: https://doi.org/10.1080/000155501750376285

    Article  CAS  PubMed  Google Scholar 

  89. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2008;128(9):2179-2189. doi: https://doi.org/10.1038/jid.2008.78

    Article  CAS  PubMed  Google Scholar 

  90. Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J. Clin. Invest. 2017;127(8):3028-3038. doi: https://doi.org/10.1172/JCI92707

    Article  PubMed  PubMed Central  Google Scholar 

  91. Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, Zhang Y, Wang F, Chen T. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc. Natl Acad. Sci. USA. 2017;114(7):1660-1665. doi: https://doi.org/10.1073/pnas.1614775114

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. V. I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russian Federation, Moscow, Russia

    I. I. Ryumina, K. V. Goryunov, D. N. Silachev, Yu. A. Shevtsova, V. A. Babenko, N. M. Marycheva, V. V. Zubkov & G. T. Zubkov

  2. A. N. Belozersky Research Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, Russia

    D. N. Silachev & V. A. Babenko

  3. M. F. Vladimirskiy Moscow Regional Research Clinical Institute, Moscow, Russia

    Yu. Yu. Kotalevskaya

Authors
  1. I. I. Ryumina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. V. Goryunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. N. Silachev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu. A. Shevtsova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. A. Babenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. M. Marycheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu. Yu. Kotalevskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. V. Zubkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. T. Zubkov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. N. Silachev.

Additional information

Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 1, pp. 3-17, March, 2021

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ryumina, I.I., Goryunov, K.V., Silachev, D.N. et al. Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects. Bull Exp Biol Med 171, 109–121 (2021). https://doi.org/10.1007/s10517-021-05182-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-021-05182-8

Key Words

Search

Navigation